< Back to previous page
Researcher
Eric Van Cutsem
- Disciplines:Oncology
Affiliations
- Digestive Oncology (Division)
Member
From1 Aug 2022 → Today - Clinical Digestive Oncology (Division)
Member
From1 Jan 2012 → 31 Jul 2022 - Translational Research in GastroIntestinal Disorders (Division)
Member
From1 Oct 1999 → 31 Dec 2011
Projects
1 - 10 of 12
- SAFIR-ABC10: molecular screening for precision medicine in advanced biliary cancersFrom1 Jan 2022 → TodayFunding: Foundations, funds and other with scientific goal
- The search for biomarkers in systemic treatment of advanced hepatocellular carcinoma.From1 Oct 2019 → 1 Oct 2023Funding: FWO Strategic Basic Research Grant
- Identification of candidate biomarkers of intrinsic and acquired resistance to anti-angiogenic agents in metastatic colorectal cancer.From1 Jan 2013 → 31 Dec 2014Funding: Private funding of national origin - undefined
- Genetic biomarkers for anti-angiogenic therapies - a translational approach.From1 Jan 2011 → 31 Dec 2013Funding: Private funding of national origin - undefined
- The role of the forkhead transcription factor FOXP1 in cancer.From1 Jan 2011 → 31 Dec 2014Funding: FWO research project (including WEAVE projects)
- Technical research platform & heavy equipment HiSeq200 (including CBOT computing system and warranty).From1 Sep 2010 → 31 Aug 2013Funding: Other federal scientific institutions
- Can response to Epidermal Growth Factor Receptor antibodies in patients with metastatic Colorectal Cancer be predicted? Advanced bio-informatics tools, integrating gene mutation, microarray and proteomics data may hold the key.From1 Jan 2009 → 31 Dec 2012Funding: FWO research project
- Imaging for early response prediction to EGF-receptor blocking monoclonal antibodies in combination therapy for colorectal cancer.From1 Jan 2009 → 31 Dec 2012Funding: IWT - TBM (Applied Biomedical Research)
- Can response to epidermal growth factor receptor antibodies in metastatic colorectal cancer be predicted? Advanced bio-informatics tools integrating gene mutation and microarray data may hold the key.From1 Jan 2009 → 31 Dec 2012Funding: Private funding of national origin - undefined
- A phase I dose-escalation study to determine the maximum tolerated dose of radiotherapy, in combination with concomitant 5-FU chemptherapy, in patients with locally advanced rectal cancer with a positive circumferential resection margin (cCRM).From1 Jan 2009 → 31 Dec 2010Funding: Private funding of national origin - undefined
Publications
581 - 590 of 726
- Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer(2010)
Authors: Eric Van Cutsem
Pages: 4706 - 4713 - Phase 2 study of XL184 (BMS-907351) in a cohort of patients (pts) with hepatocellular carcinoma (HCC)(2010)
Authors: Eric Van Cutsem
Pages: 129 - 130 - Erratum: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2- positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial (The Lancet (2010) 376 (687-697))(2010)
Authors: YJ Bang, Eric Van Cutsem, A Feyereislova
Pages: 1302 - Adjuvant Gemcitabine Alone Versus Gemcitabine-Based Chemoradiotherapy After Curative Resection for Pancreatic Cancer: A Randomized EORTC-40013-22012/FFCD-9203/GERCOR Phase II Study(2010)
Authors: Eric Van Cutsem, Karin Haustermans
Pages: 4450 - 4456 - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE III TRIAL OF EVEROLIMUS IN PATIENTS WITH ADVANCED PANCREATIC NEUROENDOCRINE TUMORS (PNET) (RADIANT-3)(2010)
Authors: Eric Van Cutsem
Pages: 4 - 5 - EVALUATION OF PROGRESSION-FREE SURVIVAL (PFS) BY BLINDED INDEPENDENT CENTRAL REVIEW (BICR) IN PATIENTS (PTS) WITH PROGRESSIVE, WELL-DIFFERENTIATED PANCREATIC NEUROENDOCRINE TUMOURS (NET) TREATED WITH SUNITINIB (SU) OR PLACEBO(2010)
Authors: Eric Van Cutsem
Pages: 235 - 235 - CETUXIMAB AND 1ST-LINE CHEMOTHERAPY IN ELDERLY AND YOUNGER PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC): A POOLED ANALYSIS OF THE CRYSTAL AND OPUS STUDIES(2010)
Authors: Eric Van Cutsem
Pages: 194 - 194 - MFOLFOX6 plus CEDIRANIB VS MFOLFOX6 plus BEVACIZUMAB IN PREVIOUSLY UNTREATED METASTATIC COLORECTAL CANCER (MCRC): A RANDOMIZED, DOUBLE-BLIND, PHASE II/III STUDY (HORIZON III)(2010)
Authors: Eric Van Cutsem
Pages: 189 - 189 - TUMOR AND BLOOD PLASMA BIOMARKER ANALYSES IN THE AVAGAST PHASE III RANDOMIZED STUDY OF FIRST-LINE BEVACIZUMAB 1 CAPECITABINE/CISPLATIN IN PATIENTS WITH ADVANCED GASTRIC CANCER(2010)
Authors: Eric Van Cutsem
Pages: 67 - 68 - The use of FDG-PET/CT and diffusion-weighted magnetic resonance imaging for response prediction before, during and after preoperative chemoradiotherapy for rectal cancer(2010)
Authors: Maarten Lambrecht, Christophe Deroose, Vincent Vandecaveye, Freddy Penninckx, Xavier Sagaert, Eric Van Cutsem, Frederik De Keyzer, Karin Haustermans
Pages: 956 - 963